Biologic Therapies for Severe Asthma: What Determines Treatment Success?
Severe asthma affects up to 10% of all asthma patients, causing frequent symptoms, recurrent exacerbations, and significantly reduced quality of life. While biologics have revolutionized treatment for these patients, their success rates vary widely—with some patients experiencing dramatic improvements and others seeing little to no benefit. The challenge? Predicting which patients will respond remains an unmet need in clinical practice.
New research highlights the critical role of biomarkers like blood eosinophil counts and fractional exhaled nitric oxide (FeNO) in guiding biologic therapy choices. Yet, despite progress, gaps remain in identifying reliable predictors for all biologics, particularly for therapies like omalizumab. Here’s what the latest evidence tells us about treatment effectiveness, biomarkers, and the future of personalized asthma care.
The Reality of Biologic Treatment Response
Biologic therapies—such as monoclonal antibodies targeting specific immune pathways—have transformed the management of severe asthma. These treatments are approved as add-on therapies for patients with moderate-to-severe, therapy-resistant asthma who remain symptomatic despite standard care.
However, not all patients benefit equally. Clinical trials and real-world data suggest that biologics achieve meaningful outcomes in approximately 60–80% of eligible patients, depending on the specific therapy and patient phenotype. The variability underscores the need for better predictive tools to match patients with the most effective treatments.
“Biologics have been a game-changer for severe asthma, but their success hinges on precise patient selection. Without reliable biomarkers, we risk undertreating some patients while exposing others to unnecessary costs and side effects.”
Biomarkers: The Key to Personalized Asthma Care
1. Blood Eosinophil Count: A Cornerstone for Anti-IL-5 Therapies
Blood eosinophil levels are the most established biomarker for guiding biologic therapy, particularly for anti-interleukin-5 (IL-5) therapies like mepolizumab, benralizumab, and reslizumab. Patients with elevated eosinophil counts (≥150–300 cells/µL) typically show the best responses to these treatments, with response rates exceeding 70% in clinical trials.
For example, a 2025 meta-analysis of 12 randomized controlled trials published in The Journal of Allergy and Clinical Immunology confirmed that patients with baseline eosinophil counts ≥300 cells/µL had a 65% reduction in exacerbations compared to placebo when treated with anti-IL-5 biologics (source).
2. FeNO: A Useful but Less Specific Marker
Fractional exhaled nitric oxide (FeNO) measures airway inflammation and is particularly useful for identifying patients who may respond to dupilumab, a biologic targeting IL-4 and IL-13. Elevated FeNO levels (≥25 ppb) correlate with type 2 inflammation and are associated with better outcomes in patients treated with dupilumab.
A 2024 study in Chest found that patients with FeNO ≥50 ppb had a 40% higher likelihood of achieving asthma control with dupilumab compared to those with lower FeNO levels (source). However, FeNO’s predictive value is less robust than eosinophil counts for anti-IL-5 therapies.
3. The Omalizumab Enigma: Why Prediction Remains Elusive
Omalizumab, an anti-IgE therapy, is approved for severe allergic asthma but lacks clear biomarkers to guide patient selection. Unlike other biologics, its efficacy isn’t strongly tied to eosinophil counts or FeNO. Recent real-world data suggest that only about 50–60% of patients experience meaningful benefits, with response rates varying widely based on individual immune profiles.
Researchers are exploring additional biomarkers, such as basophil activation markers and IgE levels, but none have yet achieved the same level of validation as eosinophils for anti-IL-5 therapies. A 2025 consensus statement from the American Thoracic Society emphasized the need for larger studies to identify omalizumab-specific predictors (source).
What This Means for Patients and Clinicians
For Clinicians: A Step-by-Step Approach to Biologic Selection
- Step 1: Confirm Severe Asthma Phenotype
Ensure the patient meets criteria for severe, therapy-resistant asthma (e.g., ≥2 exacerbations/year despite high-dose inhaled corticosteroids + long-acting beta-agonists).
Severe Eosinophilic Asthma - Step 2: Measure Key Biomarkers
- Blood eosinophil count (target ≥150 cells/µL for anti-IL-5 therapies).
- FeNO (elevated levels may indicate dupilumab suitability).
- IgE levels (for omalizumab consideration, though less predictive).
- Step 3: Match Therapy to Biomarker Profile
Biologic Primary Biomarker Guidance Estimated Response Rate Mepolizumab/Benralizumab/Reslizumab (Anti-IL-5) Eosinophils ≥150–300 cells/µL 60–80% Dupilumab (Anti-IL-4/IL-13) FeNO ≥25 ppb or eosinophils ≥300 cells/µL 55–75% Omalizumab (Anti-IgE) IgE levels ≥30–700 IU/mL (less predictive) 50–60% - Step 4: Monitor and Adjust
Assess treatment response after 3–6 months. If no improvement, consider switching to an alternative biologic or evaluating for non-type 2 inflammation.
For Patients: What to Ask Your Doctor
- What is my eosinophil count and FeNO level?
- Which biologic therapy aligns best with my biomarker profile?
- What are the potential side effects, and how will we monitor them?
- Are there clinical trials testing new biomarkers for my condition?
The Future: Toward Precision Medicine in Asthma
While current biomarkers provide valuable guidance, the field is rapidly evolving. Emerging research focuses on:
- Multi-Biomarker Panels: Combining eosinophils, FeNO, and other inflammatory markers (e.g., blood neutrophils, sputum eosinophils) to improve prediction accuracy.
- Genomic and Proteomic Profiling: Identifying genetic variants (e.g., in the IL-4/IL-13 pathways) that influence biologic response.
- Machine Learning Models: Using AI to integrate clinical, biomarker, and treatment data for personalized recommendations.
- New Therapies: Biologics targeting novel pathways (e.g., anti-TSLP, anti-IL-33) may broaden treatment options for non-type 2 asthma.
A 2026 perspective in The Lancet Respiratory Medicine highlighted that within 5 years, we may see biomarker-driven algorithms that predict biologic response with ≥90% accuracy (source). Until then, clinicians must rely on a combination of current biomarkers, clinical judgment, and shared decision-making with patients.
FAQ: Biologic Therapies for Severe Asthma
1. How long does it take to see results from a biologic therapy?
Most patients begin to experience symptom improvement within 4–12 weeks, with peak benefits often seen after 3–6 months of continuous treatment. Exacerbation reduction may take slightly longer to manifest.
2. Are biologics safe for children with severe asthma?
Yes. Several biologics, including dupilumab and mepolizumab, are FDA-approved for children as young as 6 years old (dupilumab) or 12 years old (mepolizumab), with safety profiles similar to those in adults. Pediatric studies have shown comparable efficacy to adult populations (source).
3. What are the most common side effects?
Side effects vary by biologic but may include:
- Injection-site reactions (e.g., redness, itching).
- Headaches or fatigue.
- Increased risk of infections (e.g., herpes zoster, pneumonia) due to immune modulation.
- Eosinophil-related complications (rare, e.g., vasculitis with anti-IL-5 therapies).
Regular monitoring by a pulmonologist is essential.
4. Can I stop a biologic once my asthma improves?
This depends on your individual response. Some patients achieve long-term remission and may safely discontinue biologics under close medical supervision. Others require maintenance therapy to prevent symptom recurrence. Always consult your doctor before stopping treatment.
5. Are there any biologics in development for non-type 2 asthma?
Yes. Therapies targeting neutrophilic inflammation (e.g., anti-IL-17, anti-IL-8) and mast cell stabilization are in late-stage trials. These may benefit patients whose asthma is driven by non-type 2 pathways.
Key Takeaways
- Biologics are highly effective for severe asthma but work best when matched to specific biomarkers (e.g., eosinophils for anti-IL-5 therapies, FeNO for dupilumab).
- Omalizumab remains the most challenging to predict, with ongoing research into alternative biomarkers.
- Real-world response rates range from 50–80%, emphasizing the need for personalized approaches.
- Emerging tools, including multi-biomarker panels and AI, may soon enhance prediction accuracy.
- Patients should work closely with their healthcare team to monitor biomarkers and adjust therapies as needed.
The era of one-size-fits-all asthma treatment is ending. As biomarkers and precision medicine advance, the goal is a future where every patient with severe asthma receives the right therapy—the first time—with the highest chance of success.